Potential for cognitive support and resilience.
J-147 is an experimental compound related to curcumin, crafted to boost neuroprotective properties. It crosses the blood-brain barrier, offering potential benefits for brain health.
About J-147
What is J-147?
J-147 is a synthetic compound derived from curcumin, designed to enhance neuroprotective potency and improve pharmacokinetic properties. It effectively crosses the blood-brain barrier, making it a promising candidate for central nervous system applications.
How Does It Work?
J-147 targets the mitochondrial α-F1-ATP synthase (ATP5A), modulating its activity to improve ATP production efficiency and reduce reactive oxygen species. This supports synaptic health under stress, aiding cognitive function.
Potential Benefits
Animal studies suggest J-147 might help improve memory and learning, reduce synaptic loss, and lower markers associated with Alzheimer’s-like symptoms. Its effects on inflammation and oxidative stress further emphasize its potential use.
Considerations for Use
While promising, human studies are limited. Animal safety data look encouraging, but further research is needed to confirm its effectiveness and safety in people.
Possible Combinations
J-147 could be paired with other neurotrophic agents like PQQ, CoQ10, or phosphatidylserine, especially in formulations aimed at cognitive support and mitochondrial health.
Related Products
Formulated With
Learn about other ingredients that J-147 is used alongside throughout the LVLUP range.
Detailed Information
Pharmacological Profile and Mechanism of Action
J-147 is an experimental neurotrophic compound structurally related to curcumin derivatives. It shows high permeability across the blood-brain barrier, allowing central nervous system exposure at pharmacologically relevant concentrations after systemic administration.
Molecular Target and Action
The primary target is the mitochondrial α-F1-ATP synthase (ATP5A). Modulating ATP synthase activity, J-147 adjusts mitochondrial membrane potential, enhances ATP production efficiency under stress, and reduces pathological reactive oxygen species. This supports synaptic homeostasis during metabolic demand or insult.
Signaling Pathways
J-147 also affects the AMP-activated protein kinase (AMPK) and PKA/CREB pathways, leading to increased expression of brain-derived neurotrophic factor (BDNF) and genes related to synaptic plasticity. These actions may preserve cognitive function in models of aging or proteotoxic stress.
Preclinical Data
In vivo studies show J-147 improves learning and memory in normal aging rodents and those with Alzheimer’s-like pathophysiology. It reduces synaptic loss, mitigates tau hyperphosphorylation, and lessens amyloid plaque burden. Its anti-inflammatory action includes downregulation of cytokines like TNF-α and IL-6.
Pharmacokinetics
J-147 is orally bioavailable with a moderate plasma half-life and rapid CNS uptake, primarily metabolized by hepatic cytochrome P450 enzymes into non-toxic metabolites.
Research Gaps
No large-scale human trials are complete, but early safety assessments show acceptable tolerability in animals. Ongoing research explores its effects on age-related cognitive decline, brain injuries, and mood alterations.
